Omeros Corp. (OMER) Announces Presentation of Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
Friday, clinical-stage biopharmaceutical company Omeros announced it will present additional data from recent clinical trials of OMS302, its ophthalmology project, at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium Congress, taking place April 19-23 in San Francisco. The company’s podium presentation, “Effect of an Anti-Inflammatory-Mydriatic Agent on the Incidence of Intraoperative Miosis During IOL Replacement Surgery,” will summarize key analyses of Phase 2 and Phase 3 clinical data assessing OMS302’s ability to reduce the incidence of miosis (pupil constricting) during intraoperative lens replacement surgery. These analyses will be included in both the…